Search results
Author(s):
Lori L McMullan
,
Gaston Vergara
,
Nassir F Marrouche
Added:
3 years ago
Atrial fibrillation (AF) and heart failure (HF) are two disease conditions that are intimately intertwined, both pathophysiologically and clinically. Currently, over 2.3 million people in North America and 4.5 million in the EU have AF, making it the most common arrhythmia encountered in clinical practice.1,2 It is expected that by 2050 there will be over 10 million people with AF.3 The estimated…
View more
Author(s):
Harriette Van Spall
,
John Spertus
Added:
2 years ago
Late-breaker host Dr Harriette Van Spall (McMaster University, CA) invites PI, Dr John Spertus to discuss the innovative CHIEF-HF clinical trial.
The aim of this study was to determine the superiority of the effectiveness of canagliflozin versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score …
View more
Author(s):
Ahmad Younes
,
Guilherme Ferragut Attizzani
,
Ankur Kalra
Added:
3 years ago
Transcatheter aortic valve replacement (TAVR) is a recent innovation that has transformed the care of patients with symptomatic severe aortic stenosis. It has emerged as an alternative for surgical aortic valve replacement (SAVR) in prohibitive-, high-risk, and more recently, intermediate-risk surgical patients. More than 200,000 TAVRs have been performed in 65 countries around the world.1
As…
View more
Author(s):
Harriette Van Spall
,
Mandeep Mehra
Added:
4 months ago
AHA 23 - Investigator, Dr Mandeep R Mehra (Brigham and Women's Hospital and Harvard Medical School, US) is joined by Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the ARIES HM3 trial.ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were…
View more
Clinical Utility of Realtime Three-dimensional Echocardiography - A New and Emerging Standard
Author(s):
Tamar S Polonsky
,
Victor Mor-Avi
,
Roberto M Lang
Added:
3 years ago
Article
Author(s):
William L Baker
,
William B White
Added:
3 years ago
Despite advances in diagnostic and treatment modalities, hypertension remains a prevalent medical condition, affecting over 26 % of the adult population, a number expected to rise to nearly 30 % by the year 2025.1 It is a major risk factor for cardiovascular disease morbidity and mortality, including stroke, heart failure, and renal disease.2,3 Numerous investigations have demonstrated the…
View more
Author(s):
William E Butler
Added:
3 years ago
Studies have shown that omega-3 fatty acids (FAs) can promote cardiovascular health by both primary and secondary prevention of cardiac disease, and most notably by reducing fatal cardiovascular events including sudden cardiac death (SCD). For example, recent evidence from secondary prevention trials has suggested that intake of 850mg/day of omega-3 FAs can reduce the risk of coronary heart…
View more
Author(s):
Katelyn Storey
,
Scott W Sharkey
Added:
3 years ago
During the past 25 years, takotsubo syndrome (TS) has emerged as an important form of acute myocardial injury characterized by a distinctive regional left ventricular (LV) contraction abnormality, often with marked reduction of the LV ejection fraction, and typically completely reversible. At presentation, TS is often indistinguishable from acute coronary syndrome, yet its occurrence is…
View more
Author(s):
Evan A Stein
Added:
3 years ago
Proprotein convertase subtilisin/kexin type 9 (PCSK9), discovered in 2003, is a circulating protein produced predominantly in the liver that plays a significant role in the recycling of LDL receptors (LDLRs).1,2 The LDLR, which normally recycles about 100 times in its lifetime, is the primary pathway for LDL-cholesterol (LDL-C) clearance from circulation. Plasma PCSK9 binds to LDLRs along with…
View more
Author(s):
Marvin J Slepian
Added:
3 years ago
Heart failure remains the final common pathway of all forms of heart disease. Currently, more than 20 million patients suffer with heart failure in the US and Europe combined.1 Over the past two decades, advances in medical therapeutics have made inroads in reducing mortality associated with early- and mid-stage heart failure. Unfortunately, once patients progress to advanced heart failure, i.e…
View more